Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bioequivalent or nonbioequivalent?

A Rescigno1, J Powers, E E Herderick

  • 1Stillwater, MN 55082-9278, USA

Pharmacological Research
|June 23, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Crystallization Kinetics and Polymorphic Transformations in Polybutene-1.

Journal of research of the National Bureau of Standards. Section A, Physics and chemistry·2020
Same author

Successful pregnancy after uterine artery embolization for uterine arterovenous malformation: a rare case report.

International journal of women's health·2018
Same author

Evaluation of a "walk-through" ladder top design during ladder-roof transitioning tasks.

Applied ergonomics·2016
Same author

A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195.

Investigational new drugs·2015
Same author

Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation.

Molecular oncology·2015
Same author

A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200†.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same journal

GLP-1 Receptor Agonist Therapy in Children and Adolescents with Obesity: A Network Meta-Analysis of Differential Cardiometabolic Efficacy and Safety Profiles.

Pharmacological research·2026
Same journal

Sinomenine regulates the AKT/FOXO3/GLUL pathway to inhibit pulmonary fibroblast-to-myofibroblast transition via α7nAChR against rheumatoid arthritis associated interstitial lung disease.

Pharmacological research·2026
Same journal

Ketohexokinase: A central mediator of fructose-associated pathogenesis and promising therapeutic target.

Pharmacological research·2026
Same journal

GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies.

Pharmacological research·2026
Same journal

Cajaninstilbene acid in macrophage immunometabolism and angiogenesis: Mechanisms and therapeutic potential.

Pharmacological research·2026
Same journal

From Mechanisms to Therapy: Targeting the Gut-Brain Axis in Chronic Gastrointestinal Pain.

Pharmacological research·2026
See all related articles

Current bioequivalence tests rely on flawed assumptions. This study advocates for a new method that avoids unproven general assumptions, enhancing reliability in pharmaceutical analysis.

Area of Science:

  • Pharmacokinetics and Pharmaceutical Sciences

Background:

  • Existing bioequivalence testing methodologies are founded on generalizable assumptions.
  • These assumptions are not universally valid, potentially compromising test accuracy.

Purpose of the Study:

  • To demonstrate the limitations of current bioequivalence testing assumptions.
  • To introduce and justify a novel bioequivalence assessment method.
  • To highlight the necessity of assumption-free methods in pharmaceutical analysis.

Main Methods:

  • Critical analysis of the foundational assumptions in current bioequivalence testing.
  • Development of a theoretical framework for an alternative bioequivalence assessment.
  • Comparative evaluation of the proposed method against traditional approaches.

Related Experiment Videos

Main Results:

  • Identified specific assumptions in current bioequivalence tests that lack general validity.
  • Demonstrated that the proposed method bypasses the need for these unproven assumptions.
  • Showcased the potential for increased reliability and broader applicability of the new method.

Conclusions:

  • The reliance on unproven general assumptions in bioequivalence testing poses significant limitations.
  • A new, assumption-independent method is necessary for robust bioequivalence assessment.
  • Adoption of such methods will improve the accuracy and generalizability of pharmaceutical equivalence studies.